Nervonik
Designed For Motion
- Headquarters
- Los Angeles, California
- Employees
- 1–10
- Business Model
- B2B
- Website
- nervonik.com
- Last Round
- Series AMar 2025
About
Nervonik is developing next-generation peripheral nerve stimulation (PNS) technology featuring a novel, patented trifecta system that eliminates technical barriers to biosensing in high-motion applications. The company's miniaturized devices address limitations of existing PNS devices by improving lead placement, programming flexibility, energy efficiency, and long-term efficacy. Nervonik's technology is currently under development and has not yet received FDA clearance or approval.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account